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This study, based on medical anthropology and oral reports, analyzes the meanings 
attributed by thalassemic adults to their experiences with the treatment. Interviews were 
used to collect data, which were analyzed through inductive thematic analysis. Eleven 
young adults, six of whom were men, at different ages, with different educational levels 
and occupations participated in the study. The meanings are discussed through the theme 
“the lives of patients with thalassemia in relation to their treatment”. This core meaning 
highlights the difference made in their identity by having the disease trait, the recognition 
of the importance of adhering to their treatment, the difficulties in maintaining their social 
functions, the patients’ irregular treatment adherence and their justifications for non-
adherence to their treatment. Thalassemic patients conform to their condition and employ 
a normalization strategy to control the disease and justify irregular treatment adherence.
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A experiência dos talassêmicos adultos ao tratamento
O objetivo neste estudo foi analisar os sentidos dados pelos talassêmicos adultos à sua 
experiência em relação ao tratamento, com base na antropologia médica e no método do 
relato oral. Para a coleta de dados, usaram-se entrevistas e seguiu-se a análise temática 
indutiva. Participaram onze adultos jovens, seis do sexo masculino; com idades, níveis 
educacionais e profissões distintas. Os sentidos são apresentados pelo tema “a vida do 
portador de talassemia com o tratamento”. O tema destacou a identidade de diferença 
pelo traço da doença, o reconhecimento da importância da adesão ao tratamento, 
as dificuldades em manterem suas funções sociais, os episódios de irregularidade na 
terapia e suas justificativas. Apreendeu-se que os portadores estão resignados com 
sua condição, empregam a estratégia de normalização para o controle da doença e 
justificaram a irregularidade no tratamento.
Descritores: Talassemia Beta/terapia; Cultura; Enfermagem.
La experiencia de los talasémicos adultos con su tratamiento
El objetivo de este estudio fue analizar los sentidos dados por los talasémicos adultos a 
su experiencia con el tratamiento, con base en la antropología médica y en el método 
del relato oral. Para la recolección de datos usamos entrevistas y seguimos el análisis 
temático inductivo. Participaron once adultos jóvenes, seis del sexo masculino; con 
edades, niveles educacionales y profesiones, distintas. Los sentidos da la experiencia son 
presentados por el tema “La vida del portador de talasemia con el tratamiento”. El tema 
destaca la identidad de ser diferente por: el trazo de la enfermedad, el reconocimiento de 
la importancia de la adhesión al tratamiento, las dificultades en mantener sus funciones 
sociales y los episodios de irregularidad en la terapia y sus justificaciones. Aprendimos 
que los portadores están resignados con su condición y emplean la estrategia de 
normalización para el control de la enfermedad y para justificar la irregularidad en el 
tratamiento.
Descriptores: Talasemia Beta/terapia; Cultura; Enfermería.
Introduction
Forms of thalassemia belong to a group of genetic 
diseases called hemoglobinopathies that compromise the 
normal production of chains of alpha and beta globins, 
which form hemoglobin. The incidence of thalassemia 
in Latin America and the Caribbean is heterogeneous, 
about 1% to 2% of the population. It was introduced 
by Portuguese, Spanish and Italian immigrants. The 
prevalence of thalassemia major, which is the most 
severe clinical form, is greater in the south and southeast 
of Brazil, affecting 1% of the population(1).
Signs and symptoms of the disease emerge at 
the end of the first year of life and disappear with the 
diagnosis and beginning of treatment, and growth goes 
back to normal. If treatment is not initiated, the child 
may present severe general complications and die within 
the first or second decade of life(1-2).
Because of advanced knowledge concerning the 
disease and the effects of therapies, health professionals 
currently care for patients with thalassemia who have 
reached adult age. Treatments for thalassemia major 
include regular, lifetime, transfusions of red blood 
cells associated with iron chelation therapy. Although 
repetitive transfusions are a palliative therapy, it enables 
patients to develop normally, improve their quality of life 
and reach adult age(1).
The transfusion scheme recommended for 
individuals with thalassemia major is approximately 100 
to 200 ml of concentrated red cells per kg/year aiming to 
maintain blood hemoglobin between 9.0 g/dl and 10.5 g/
dl. Repetitive transfusions cause complications such as: 
hemolytic reactions, alloimmunization, the possibility of 
seroconversion, and, mainly, the accumulation of iron in 
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various organs. This accumulation leads to retardation of 
growth and sexual maturation, endocrine abnormalities, 
among other problems, although cardiac complications 
are more severe and account for 50% of deaths(3).
There are three types of iron chelators employed 
in clinical practice: 1) Desferrioxamine (Desferal) must 
be subcutaneously or intravenously infused by pump at 
night on a regular basis: five or more times a week; 2) 
Deferiprone was the first oral chelator to be licensed; 
its employed dose is divided into three daily doses; 3) 
Exjade (Deferasirox) is taken in a daily single dose via 
various effervescent tablets. These drugs have different 
actions on the various organs and their combined use 
may optimize the iron chelating effect without, however, 
increasing the intensity of side effects. The therapy has 
to be personalized to each patient according to each 
one’s profile of iron overload and clinical condition(3).
The use of oral chelators is recent. Patients using 
them follow a monthly medical monitoring regime due 
to resulting organic reactions and have their kidney 
functions and ferritin assessed(1).
The interruption of transfusions and/or chelator 
infusions does not immediately induce symptoms. 
Prolonged interruptions, though, worsen the patient’s 
physical condition and iron concentration in different 
organs may increase, leading to an irreversible condition 
and death(1).
For optimum adherence, the patient needs to 
attend a specialized service at least once a month for 
screening tests and a subsequent blood transfusion, 
introduce Desferal subcutaneously by infusion pump for 
eight hours daily, for a limited period, and/or ingest the 
appropriate dose of Deferiprone and/or Deferasirox.
Non-adhering patients with thalassemia major 
are reported by various authors(2-3) and are a cause for 
concern. However, no Brazilian study addressing the 
socio-cultural elements influencing the experience of 
patients with treatment was found. Such knowledge can 
facilitate nursing care and also care provided by other 
professionals, which indicates the importance of this 
study.
The following questions are expected to be 
answered in this study: How do patients perceive their 
treatment? What is it like to be obligated to submit to 
treatment for life? What are the reasons one does or 
does not adhere to treatment? What is life like under 
a therapeutic regime? The meanings held by adult 
thalassemic patients concerning their experience with 
the therapeutic regime are analyzed in this study.
The impact of thalassemia major and its 
treatments on the life of adult patients
A study addressing treatment adherence among 
40 American individuals older than 18 years old showed 
that 37 of them used chelators through infusion; 77% 
of them had missed at least one dose in the previous 
month due to its side effects such as pain and irritation 
at the application site. The authors concluded that the 
chelator’s side effects are responsible for non-adherence 
to treatment(4).
The expectations of thalassemic individuals in 
relation to life composed the topic of a study involving 
67 Greek patients aged between 18 and 45 years old. 
Of these, 75% had a bachelor’s degree, 71% worked, 
67% had negative treatment adherence and 77.6% 
had important complications. The results showed that 
pessimism in relation to the future was predominant 
among those with complications and lower levels of 
education; a better expectation in relation to life was 
observed among men(5).
The hypothesis that the greater the knowledge 
one has in relation to a disease, the greater treatment 
adherence was investigated in a group of 32 patients, 
aged on average 17 years old. The results confirmed 
such a hypothesis: 43% had inaccurate knowledge of 
the disease and treatment and only 48% adhered to the 
therapeutic regime(6).
Authors related educational level and occupation 
with other factors such as age, sexual and ethnical 
characteristics, therapeutic regime (transfusion and 
chelation) and clinical complications in a sample of 349 
American and Canadian adults with thalassemia major. 
The results indicated that 70% of adults were employed 
and 60% had an average educational level. Caucasian 
individuals worked in better-recognized professional 
activities; work was more frequent among older women 
without clinical complications. The authors concluded 
that neither transfusion nor chelation is a factor that 
hinders educational and professional development(7).
One of the themes receiving more focus in studies 
is quality of life among thalassemic individuals in 
different age ranges. Unfortunately, these present 
contradictory results. One of these studies was of 
special interest because it included individuals from 
the same facility where this study was conducted and 
individuals presented similar social characteristics(8). It 
involved 10 young adults aged between 22 and 28 years 
old through semi-structured interviews whose answers 
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were analyzed according to content. Different scales 
were used to evaluate the participants’ psychological 
conditions. The comparative analysis of the results on 
two points of the evaluation suggested that the quality 
of life of patients going into adult life was harmed and 
some presented increased psychological symptoms.
The experience of British young adults with 
thalassemia undergoing chelation therapy was the 
object of a socio-anthropological study(9-10). A total of 25 
individuals, 12 of which were men and 23 were students, 
ages ranging from 10 to 19 years old, participated in 
the study. The authors assert, based on the obtained 
narratives, that the response of the individuals to the 
need for chelation therapy represents a rupture in their 
lives and is part of a broader process in which they give 
meaning to the treatment by relating it to the body, 
identity and maintenance of their relationships. The 
daily experiences of chelation therapy, the patients’ 
family relationships and those held with social networks 
are all implicated in the issue of adherence.
Papers(4-10) addressing the disease’s psychosocial 
aspects and treatment regimens for adult patients are 
not abundant. Therefore, there is limited knowledge 
concerning this population, especially in the Brazilian 
context.
Theoretical and methodological framework
The theoretical structure of medical anthropology, 
the branch of the interpretative anthropology, which 
connects health, disease and culture was used in 
this study. Culture is seen as a system of meanings 
constructed in social life and shared with a group of 
which one is a part, providing parameters for how one 
thinks and acts. Medical anthropology views disease 
as a process characterized by the acknowledgement 
of its disorders, diagnosis, choice of treatment and 
evaluation. The disease and treatment are also 
experiences, because the body for the human being 
is a symbolic matrix that organizes one’s experiences, 
relating them to the social, natural and cosmological 
worlds. Both disease and treatment generate bodily 
changes and these can be seen as a subjective reality 
where the body, perception, and meanings are united 
in a single interpretation(11).
Medical anthropology distinguishes the constructions 
of ‘disease’ –the perspectives of biomedical objectivity 
and ‘illness’—which is the patient’s perspective, focused 
on subjectivity and includes the disease’s cultural, 
social and personal elements(12). For one to learn the 
similarities and differences among the perspectives 
of patients in the course of a chronic disease and 
treatment, one should explore the treatment’s objectives, 
strategies, and evaluation criteria. Because explanations 
involve multiple and often contradictory processes and 
meanings, they are seen as situational explanations(13).
This approach is designed to associate the meanings 
held by thalassemic individuals concerning their 
therapeutic regime beyond the biomedical model that 
separates the body from one’s socio-cultural life, and 
its consequences for treatment adherence, integrating 
values, beliefs, and symbols linked to gender, age, socio-
economic class and social roles.
The analysis of individual’s treatment experience 
can be carried out through narratives that allow 
creations based on circumstances, actions, causes, 
relations, objectives and means, leading the researcher 
to an interpretative posture that promotes a reciprocity 
between popular and scientific thinking, uniting cultural 
and religious structures, common sense, media and 
medical services. The narratives can be obtained through 
the oral report technique and interviews. An oral report 
is an instrument to understand the meaning of human 
action, a person’s social relationships that compose the 
environment within which individuals move(14).
Study procedures
The study was developed at the Hematology Center 
of Ribeirão Preto linked to the Hospital das Clinicas 
at University of São Paulo at Ribeirão Preto, Medical 
School. Eleven patients with thalassemia major receiving 
treatment from this service and who returned for a 
monthly medical evaluation from January to April, 2010 
and met the following inclusion criteria were invited to 
participate: being 18 years old or older, either gender, 
with different socio-economic and educational levels.
All the invited individuals met the inclusion criteria 
and agreed to participate. After the individuals signed 
free and informed consent forms, the first interview was 
scheduled for the following return medical visit.
Data were collected through semi-structured 
interviews guided by an instrument composed of two 
parts: the first addressed the participants’ social 
characteristics; the second part included questions 
that facilitated the individuals’ narratives: How did the 
disease start? What do you think about the treatments? 
How do you deal with them? Have you ever stopped 
your treatment? Why? What do you think about having 
to have treatments for life?
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The interviews were conducted during blood 
transfusion sessions, were recorded with the 
authorization of patients and took between 30 and 40 
minutes. Two interviews were conducted with each 
patient; the second clarified doubts arising from the 
initial data analysis. Interviews were fully transcribed 
and texts were submitted to inductive thematic analysis. 
This type of analysis consists of an interpretative 
process of analyzing data according to common 
aspects, relationships and differences among them. A 
theme is a general aspect that aggregates data. This 
process involves the following stages: 1) global reading 
of material; 2) detailed reading of each text to check 
for similarities, differences and details of narratives, 
classifying them into codes; 3) delimitation of common 
and different meanings expressed by the participants, 
which enabled the construction of descriptive categories 
concerning the object; 4) discussion of results (themes) 
based on the participants’ contexts of life, the theoretical 
framework and available literature(15).
Data were classified into descriptive or empirical 
categories in the first stage of analysis: signs and 
symptoms of the disease, beginning of treatment, current 
treatment, repercussions of treatment, adherence and 
non-adherence, future prospects. From these categories 
the thematic core emerged: “the life of patients with 
thalassemia in relation to their treatment”.
Among the rigor criteria the following are highlighted: 
being engaged with patients for a period of four months; 
considering the patients’ different perspectives using 
their narratives as examples; involvement of patients 
of different economic classes and educational levels 
and both genders; and working with another researcher 
using the same theoretical-methodological approach to 
construct the categories and theme(15).
The project was submitted to and approved by 
the Research Ethics Committee at the University of São 
Paulo at Ribeirão Preto, Medical School, Hospital das 
Clinicas (process No. 11498/2009, November 9th 2009). 
The patients were ensured of their right to be informed 
about the study and freely consent to participate in it, as 
well as being ensured of the confidentiality of provided 
information and identity. Hence, fictitious names are 
used throughout the text to name the participants.
Results
- Identification of participants: the group of 
participants was composed of six men and five women 
aged between 22 to 32 years old; educational level 
varying from vocational programs to bachelor’s degrees; 
income between 1.17 to 5.88 times the minimum 
wage, while one was a student and had no income and 
another was on sick leave receiving financial support 
from the government. Their occupations varied: four 
salesmen, one cashier, a mechanic, a laundry assistant, 
a musician, a general services assistant, a student, and 
one unemployed. In relation to religion, ten reported to 
be Catholic, six of which were non-practicing Catholics. 
Ten lived in Ribeirão Preto and one in another state. 
These social characteristics characterize the group as 
young adults of a productive age. Despite their education 
– vocational courses and some with a bachelor’s 
degree—their occupations do not receive much social 
acknowledgement, showing the difficulty of reconciling 
a professional activity with the therapeutic regime, even 
though Brazilian laws favor such integration.
- thematic core “the life of patients with thalassemia 
in relation to the treatment”: The participants reported 
that the disease’s symptomatology emerged in their first 
years of life, and at the time their parents identified it as 
anemia. The exacerbation of symptoms or the onset of 
other symptoms, led them to seek out health services. 
The therapeutic development within the health system 
was characterized by difficult access and lack of problem-
solving capacity. We lived in Paraná at the time and my father 
sought out all kinds of physicians to find out what the problem 
was. My spleen would swell, I was weak and couldn’t walk… 
Since my father and my mother had the same trait, they sent 
me to Curitiba and they found out I had thalassemia. (Maria, 27 
years old); According to my mom, I was six months old. Then I 
had anemia, profound anemia. Then the doctors took too long 
to figure out the anemia’s origin. They sent me to Jaboticabal 
and then they referred me here. Then, they found out that I had 
thalassemia major. (Diego, 28 years old).
When the participants talk about the disease, 
they use appropriate medical vocabulary that gives 
meaning to the disease and treatment: I have the trait, 
anemia, thalassemia major, separation of leukocytes, red blood 
cell concentrate, my ferritin. This use denotes they have 
learned and applied the information provided by the 
service professionals.
Among the meanings given to the experience of 
many years with a therapeutic regime implemented for 
a genetic and chronic disease, there is a relationship 
with the concept normal, presented by most patients; 
for others the relationship was presented as resignation. 
Normal! Because I already had in my mind that I had a problem 
and would have to do the treatment. So, for me it was normal, 
I got it alright. (Maristela); For me, it was like… normal! When 
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you’re born with something, it’s easier. I’ve always been ok with 
it, never had many problems. (Joana); […] I know I need the 
treatment to get well. So, there’s not much I can do. I know 
it will be like this my entire life, you get used to it. I need the 
treatment to live. (Rita); We have to conform! What can we do? 
I have to do it! (Diego).
Nicolas, 25 years old, makes clear that the 
experience is only suffered, Today, for me it’s normal! To 
tell the truth, there’re times I get fed up! Having to come here 
[…]. (Nicolas).
The difficulties in dealing with the therapeutic 
regime are varied. Considering the social characteristics 
of the participants, work, leisure, body image and 
the maintenance of loving relationships are the most 
negatively impacted. […] it was difficult to find a job because 
of it. Most jobs do not accept it when you miss work, you 
know. (Maria); I’m coming here every two weeks because my 
hemoglobin is too low. It is difficult, my boss doesn’t like it, I take 
the doctor’s attestation but I know he doesn’t like it. I told him 
about the disease when I accepted the job, that I had to have 
transfusions. He got a little uneasy, you know […] the worst is 
not getting the treatment… is the fact that I have to come here! I 
lose the entire day. Now it is even worse because I have to come 
twice a week. (Rita); In the summer, swimming suits, swimming 
pool and all, and my body is all bruised , there’re hematomas 
everywhere, the skin is red, purple. Sometimes, there’re lumps, 
visible ones! If you look carefully, you’ll see lumps coming out 
of the skin! (Joana).
In addition to the difficulties in reconciling social life 
and treatment, the medication needs to be appropriate 
to the clinical condition of each individual. It implies 
periodically trying new drugs, dealing with their reactions 
and setbacks: I had a lot of iron impregnated in my heart. Then 
the doctor said for me to come here at least two months in a row 
to have the pulse therapy! I came every day in a month. Then 
I asked him to give me 15 days to rest. My body couldn’t take 
it anymore! The body and mind! Then, I took Deferiprone, and 
it gave me a lot of stomachaches! So I had to stop it. Now, I’ve 
started with Exjade since last month, but I had an allergic reaction 
to it and I went back to the Desferal back, for now (Diego).
Some also expressed reactions to the severe 
consequences of interrupting medication. Ah, I didn’t do 
the treatment right. Every type of chelator you can imagine I’ve 
already taken! But I didn’t accept it at the time! I’d go away and 
not have to have pulse therapies; I’d go long periods without 
treatment and then I had heart failure and cardiac arrest! Then I 
realized what was happening (Leonardo); I’ve seen many friends 
my age with thalassemia and who unfortunately died over the 
course of their treatment because they didn’t take the treatment 
seriously […] (Miguel).
Hence, the reports showed that the patients 
acknowledge the importance of maintaining regular 
treatment for their survival.
The patients reported experiences with social stigma 
given the disease and especially for having to periodically 
attend return visits and undergoing transfusions. 
Consequently, they do not always reveal that they have 
the disease. Ah, there’s still much prejudice! People are afraid! 
I’ve heard people saying I’m a risk. (Leonardo); […] I don’t tell 
people I do transfusions! I don’t like to talk about it. (Igor).
When the patients were asked if they ever interrupted 
their treatment, most denied doing so but made clear 
that this practice occurred in different situations, which 
are exemplified in the followed reports: Today, I didn’t 
take the chelator because it gives me diarrhea and I was afraid 
of having it on the way here. But my ferritin is 900. I know that 
if I don’t take the drug, it may worsen […] (Rita); […] I used to 
say that I was a normal person, only had to have the transfusion 
once a month. I went one week without Desferal and my ferritin 
went up. It’s so tiresome! Every day you get pricked, gets lumps 
and you don’t manage to do it. You get home late, tired… So, I’d 
say: today I won’t do it! (Francisco); Now, my ferritin increased 
because I forgot to take the medication (Livia).
Some have hope and expectations for the future 
that less aggressive therapies will emerge; others have 
only strength to keep surviving: I wish they’d invent some 
other treatment to increase hemoglobin, that I didn’t have to 
have these blood transfusions. I wish there was a pill so I didn’t 
have to have transfusions. Who knows, perhaps some day, 
right! (Rita); I hope that I have to come here less often from 
now on. (Francisco); I expect that in the future… I’ll develop 
professionally, I’d be better! In relation to the treatment, a tiny 
pill with a blood bag (Nicolas); I don’t stop to think about the 
future! (Diego).
Discussion
The reports show that being an adult with 
thalassemia major is a difficult experience due to the 
frequency of return medical visits, periodic transfusions, 
the daily use of medication, side effects caused by the 
transfusions and medications, and social stigma, that 
alter daily life, as revealed in the literature(4-8).
The facility’s professionals constantly inform the 
patients about the need to continue their treatment 
to ensure their survival, and these are aware of their 
“genetic trait” (being an individual with thalassemia). 
This acknowledgment leads them to conform to their 
situation, we have to conform to our situation. It 
implies in not fighting reality, but trying to live with 
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it(16). Additionally, the way they approach their clinical 
conditions – my ferritin, and the use of medications 
– I’m using Exjade, are evidence of the fact that they 
have incorporated their disease and treatment(17). That 
is, disease, treatment and body begin to constitute a 
single identity.
Symbolically, every person has an individual body 
(physical and psychological) that is acquired at birth and 
a social body that is necessary to live in a given cultural 
group. The social body is the essence of body image 
and self-image, because it provides a frame through 
which the person perceives and interprets physical and 
psychological experiences. It is also a means through 
which society controls behavior in disease and health, 
in working and leisure activities(18). The idea that the 
sick body is a mediator of social relations has meaning 
in the case of chronic diseases given these diseases’ 
characteristics. The disease does not exclude the 
patient from daily life but is at the center of one’s social 
relationships, that is why one conforms to the situation; 
one of the patient’s objectives is to reduce derangement 
caused by such an experience. For that, thalassemic 
patients employ the strategy of normalizing body and 
life to control the disease, the treatment and social 
reinsertion. Normalizing life does not mean to return to 
life without the disease, but it is a set of actions and 
interpretations that allows one to construct a natural 
attitude, a new way to live life, at least in part, according 
to the social values and standards of the individuals 
involved(16).
Hence, interrupting treatment is not an attitude of 
defiance or ignorance, but an expression of the need 
to normalize one’s body and life, though it does bring 
severe consequences and pose risks to the survival 
of patients, who at the same time acknowledge such 
consequences.
In this context, treatment adherence is not a 
matter of practical difficulty; it symbolizes a threat 
to the normality of life –one of the processes through 
which power is manifested in the field of identity and 
difference; normalizing means attributing to identity all 
the possible positive characteristics, because a normal 
identity is desirable(19).
The process of normalization as a strategy to 
cope with the disease is culturally learned and valued. 
It enables one to deal with anguish, uncertainty and 
suffering, and is a common view of the chronic condition 
as shown in Brazilian papers addressing the experience 
of adult oncologic patients undergoing therapy(20-21).
When discussing the challenges associated with 
prolonging the survival of patients with thalassemia, from 
childhood to adulthood, authors(22) emphasize that adult 
patients spend on average 271 hours per month in care 
(transfusions, medication therapy, medical consultation 
and travels), which illustrates what treatment adherence 
really means.
The comparison of the meanings held by young 
adult individuals in this study with those of the British 
study(9-10) with the same theoretical-methodological 
approach revealed they are similar and we agree with 
the authors who highlight emotional and social concerns 
and explain why chelation therapy adherence is irregular 
and varies among individuals over time.
The overlap of different meanings concerning the 
care process is worth noting in relation to the survival 
of thalassemic individuals. Chronic transfusion patients 
consider their problem constructed and structured 
by the desired to be normal (without the need to 
have transfusions and take Desferrioxamine). For the 
health professionals, the matter is to keep patients 
alive through a therapeutic regime based on medical 
knowledge. While all are focused on the same problem, 
each has a different emphasis concerning its meanings. 
It generates oppositions and different priorities. But 
what matters most is to recognize that patients respond 
differently to therapies(23).
We agree with a hematologist who says that even 
when there is success in maintaining chelation therapy, 
the patient is always between two polarized situations, 
that is, between the devil and the deep sea –toxicity 
by iron and toxicity by chelation. The patient does 
not directly feel the effects of iron excess or those of 
chelation; he can only imagine how harmful it can be to 
not regularly adhere to therapy(19).
Hence, we see that therapy adherence is a process 
through which patients follow alternative paths that 
enable the feeling of satisfaction; s/he absorbs, analyzes, 
interprets, and reacts according to his/her knowledge, 
values and beliefs (culture), and decides whether to 
continue following a given treatment or not. Family and 
friends, rarely health professionals, help the patient with 
this decision. This influence demonstrates the power of 
the social network in one’s decision-making process 
concerning care provided to health and disease(19).
Final considerations
The thematic core indicates that the 11 young 
adults with thalassemia major, regardless of gender, 
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age, religion and social economic level, narrated their 
experiences with treatment, mediating their bodies and 
emotions so that their histories give meaning to their 
limited bodies, to experience some degree of normality 
in life. That is why they irregularly follow the chelation 
treatment, contrary to the regularity of therapeutic 
adherence expected in the medical model. They justify 
such irregularity given the limitations imposed on social 
functions, exposing themselves to risks that threat their 
survival.
In this context, we assert that nurses need to 
understand the difficulties faced by patients, acknowledge 
their cultural values and support them in their therapy’s 
different phases while working jointly with family 
members. A support group during the outpatient’s return 
visits can be an intervention strategy used by patients 
to express and discuss their feelings concerning the 
disease, treatment and how these impact their lives.
We suggest that this topic be further explored 
through prolonged data collection, with a larger number 
of participants, employing participant observation in the 
family context. Such strategies can enable the collection 
of narratives with a greater variability of experiences 
with therapeutic regimes.
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